SCHEMBL3608585

SCHEMBL3608585

CCCCNc1ncccc1-c1nc(Nc2cccc(Cl)c2)ncc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17A Q9UEE5 9/20 0.45
STK17B O94768 3/20 0.44
SIRT5 Q9NXA8 1/20 0.44
SYK P43405 1/20 0.43
AXL P30530 1/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
JAK3 P52333 1/20 0.41
CDK1 P06493 4/20 0.41
CDK4 P11802 2/20 0.41
CCNB1 P14635 2/20 0.41
CCNA2 P20248 2/20 0.41
CCND1 P24385 2/20 0.41
CDK2 P24941 2/20 0.41
CDK7 P50613 2/20 0.41
CCNH P51946 2/20 0.41
CDK5 Q00535 2/20 0.41
CDK5R1 Q15078 2/20 0.41
NPC1 O15118 1/20 0.41
CCNT1 O60563 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3608844 0.91 STK17A (0.56) STK17ASTK17B
SCHEMBL3609399 0.87 SIRT5 (0.49) STK17ASTK17BSIRT5SYKJAK2
SCHEMBL3608858 0.86 AXL (0.41) STK17ASTK17BSIRT5SYKAXL
SCHEMBL3616045 0.81 SYK (0.52) SYKAXLJAK2JAK1JAK3
SCHEMBL3592504 0.76 SYK (0.50) SYKAXLJAK2JAK1JAK3
SCHEMBL3605884 0.74 CDK2 (0.53) CDK1CDK4CCNB1CCNA2CCND1
SCHEMBL3603990 0.73 CAMK2D (0.60) STK17ASTK17BSYKCDK1CDK4
SCHEMBL3613553 0.73 CDK1 (0.67) CDK1CDK4CCNB1CCNA2CCND1
SCHEMBL3610465 0.73 CAMK2D (0.60) STK17ASTK17BSYKCDK1CDK4
SCHEMBL3613529 0.73 MAPT (0.54) CDK1CDK4CCNB1CCNA2CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048597-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-02-25 US disclosed
US-20100048597-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-02-25 US disclosed
US-20100048597-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048597-A1 Organic Compounds and Their Uses OAT, OTC, AOX1 STK17A 4710/4885STK17B 4591/4885SIRT5 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.